Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy

• Published in: Lipids in health and disease Vol. 11; no. 1; p. 143
• Main Authors: Glueck, Charles J, Khan, Naseer, Riaz, Muhammad, Padda, Jagjit, Khan, Zia, Wang, Ping
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.10.2012; BioMed Central; BMC
• Subjects: Aged; Blood pressure; Body Weight; Care and treatment; Cholesterol; Diabetes; Diabetes therapy; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Combinations; Drug dosages; Eicosapentaenoic Acid; Fatty acids; Fatty Acids, Omega-3 - administration & dosage; Fatty Acids, Omega-3 - adverse effects; Female; Genotype & phenotype; Glucose; Humans; Hyperlipidemia; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - adverse effects; Lipoproteins; Lovaza; Male; Middle Aged; Severe primary hypertriglyceridemia; Statistical analysis; Triglyceride; Triglyceride-lowering therapy; Triglycerides; Triglycerides - blood; Type 2 diabetes
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/1476-511X-11-143

Omega-3 fatty acids are important in treatment of severe primary hypertriglyceridemia (HTG). In 15 patients with severe primary HTG (TG >500 mg/dl despite conventional TG lowering therapy), we assessed efficacy-safety of sequential monthly treatment with Lovaza, 4 to 8 to 12 g/day. With TG >500 mg/dl despite Type V diet, hyperinsulinemia and diabetes control, and fibric acids, Lovaza (4 g/d) was added for 1 month, and if TG remained >500 mg/dl, increased to 8 g/d for 1 month, and then to 12 g/d for 1 month, and subsequently reduced to 4 g/day for 4 months. Primary HTG, median TG 884 mg/dl, 14 men, 1 woman, all white, age 50 ± 7 years, 12 non-diabetic, 3 with stable diabetes control. Weight and diet held stable throughout. In 5 patients, after 1, 2, and 3 months on 4 g/day, TG fell <500, mean 1390 to 234 (-83%, p<.0001), to 135 (-90%, p<.0001), and 158 mg/dl (-89%, p<.0001), with a negative TG slope, p=.0013. Non-HDLC fell from 320 to 177 (-45%, p=.001), to 152 (-53%, p=.0002), and to 163 (-49%, p=.0004), with a negative slope, p=.01. In 10 patients, with Lovaza increased from 4 to 8 to 12 g, 3 failed to respond. In 7 of these 10 patients, TG fell 37% from 1075 to 672 on 4 g (p=.006), to 577 on 8 g (-46%, p=.0009), and to 428 mg/dl (-60%, p<.0001) on 12 g/day, with a negative TG slope, p=.0018. TG on 12 g/day was lower than on 8 g/day, p =.03. Non-HDLC fell from 245 to 217 mg/dl (-11%) on 4 g/day, to 203 (-17%, p=.01) on 8 g/day, and to 192 (-22%, p=.003) on 12 g/day, with a negative slope, p=.016. Compared to pre-Lovaza baseline, no abnormal measures developed in safety tests. The 4, 8, and 12 g/d Lovaza doses were well tolerated. Titration of Lovaza from 4 to 8 to 12 g/d safely offers an effective way to lower TG beyond conventional 4 g therapy.